Inventor
GILLIGAN PAUL J
US38 patents
⚠️ This page may combine multiple inventors who share the name “GILLIGAN PAUL J”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BRISTOL MYERS SQUIBB CO
12 patentsUS8367709B2Feb 5, 2013
Dipeptide analogs as coagulation factor inhibitors
BRISTOL MYERS SQUIBB CO42 citations94
US7626039B2Dec 1, 2009
Arylpropionamide, arylacrylamide, ayrlpropynamide, or arylmethylurea analogs as factor XIa inhibitors
BRISTOL MYERS SQUIBB CO14 citations92
US6525056B2Feb 25, 2003
Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (CRH) antagonists, useful for treating cns and stress-related disorders
BRISTOL MYERS SQUIBB CO22 citations92
US9902742B2Feb 27, 2018
Macrocycles as factor XIa inhibitors
BRISTOL MYERS SQUIBB CO5 citations84
US9611274B2Apr 4, 2017
Macrocycles as factor XIa inhibitors
BRISTOL MYERS SQUIBB CO5 citations84
US7144894B2Dec 5, 2006
Sulfonamide bicyclic compounds
BRISTOL MYERS SQUIBB CO9 citations74
US7842708B2Nov 30, 2010
Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors
BRISTOL MYERS SQUIBB CO4 citations62
US9376444B2Jun 28, 2016
Dihydropyridone P1 as factor XIa inhibitors
BRISTOL MYERS SQUIBB CO0 citations52
US9108981B2Aug 18, 2015
Cyclic P1 linkers as factor XIa inhibitors
BRISTOL MYERS SQUIBB CO0 citations52
US6960583B2Nov 1, 2005
Pyrazolotriazines as CRF antagonists
BRISTOL MYERS SQUIBB CO0 citations52
US9951071B2Apr 24, 2018
Dihydropyridone P1 as factor XIa inhibitors
BRISTOL MYERS SQUIBB CO0 citations51
US9409908B2Aug 9, 2016
Dihydropyridone p1 as factor XIa inhibitors
BRISTOL MYERS SQUIBB CO1 citations51
BRISTOL MYERS SQUIBB PHARMA CO
9 patentsUS6589952B2Jul 8, 2003
Imidazo[1,2-a]pyrazines for the treatment of neurological disorders
BRISTOL MYERS SQUIBB PHARMA CO30 citations92
US7358252B2Apr 15, 2008
4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
BRISTOL MYERS SQUIBB PHARMA CO4 citations74
US7157578B2Jan 2, 2007
4-(2-butylamino)-2, 7-dimethyl-8-(2-methyl-6-methoxypyrid-3-YL) pyrazolo-[1,5-A]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
BRISTOL MYERS SQUIBB PHARMA CO6 citations74
US6958341B2Oct 25, 2005
Pyrazolopyrimidines as CRF antagonists
BRISTOL MYERS SQUIBB PHARMA CO8 citations73
US7662817B2Feb 16, 2010
4-(2-Butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-[1,5-A]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
BRISTOL MYERS SQUIBB PHARMA CO3 citations63
US7319100B2Jan 15, 2008
Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
BRISTOL MYERS SQUIBB PHARMA CO3 citations62
US7205306B2Apr 17, 2007
Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
BRISTOL MYERS SQUIBB PHARMA CO2 citations62
US7026317B2Apr 11, 2006
Pyrazolotriazines as CRF antagonists
BRISTOL MYERS SQUIBB PHARMA CO0 citations52
US7153961B2Dec 26, 2006
Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist
BRISTOL MYERS SQUIBB PHARMA CO0 citations39
DU PONT MERCK PHARMA
7 patentsUS5532243AJul 2, 1996
Antipsychotic nitrogen-containing bicyclic compounds
DU PONT MERCK PHARMA47 citations92
US5169855ADec 8, 1992
Piperidine ether derivatives as psychotropic drugs or plant fungicides
DU PONT MERCK PHARMA41 citations92
US5296479AMar 22, 1994
Treatment of psychosis using 1-cycloalkylpiperidines
DU PONT MERCK PHARMA6 citations73
US5109002AApr 28, 1992
Antipsychotic 1-cycloalkylpiperidines
DU PONT MERCK PHARMA13 citations73
US5116846AMay 26, 1992
N-aralkyl piperidine derivatives as psychotropic drugs
DU PONT MERCK PHARMA6 citations62
US5266572ANov 30, 1993
Antipsychotic 1-cycloalkylpiperidines
DU PONT MERCK PHARMA0 citations41
US5243048ASep 7, 1993
Antipsychotic 1-cycloalkylpiperidines
DU PONT MERCK PHARMA0 citations41
PINTO DONALD J P
3 patentsUS9221818B2Dec 29, 2015
Macrocycles as factor XIa inhibitors
PINTO DONALD J P13 citations92
US8604056B2Dec 10, 2013
Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors
PINTO DONALD J P0 citations51
US8252830B2Aug 28, 2012
Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors
PINTO DONALD J P0 citations51
DU PONT PHARM CO
3 patentsUS6245769B1Jun 12, 2001
Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone(CRH) antagonists, useful for treating CNS and stress-related disorders
DU PONT PHARM CO25 citations92
US6174912B1Jan 16, 2001
Nitrogen substituted imidazo[4,5-C]pyrazoles as corticotropin releasing hormone antagonists
DU PONT PHARM CO21 citations84
US6103737AAug 15, 2000
Aryl- and arylamino- substituted heterocycles as corticotropin releasing hormone antagonists
DU PONT PHARM CO15 citations72
PFIZER
3 patentsUS4636506AJan 13, 1987
7-heterocyclic-1,4-dihydroquinolones
PFIZER25 citations91
US4623650ANov 18, 1986
Antibiotic derivatives of 7-phenyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids
PFIZER43 citations91
US4797490AJan 10, 1989
Process for the preparation of 3-(2'-fluorophenyl)pyridine
PFIZER11 citations72